Biological Therapy in Treating Patients With Prostate Cancer
Completed · Phase 1/Phase 2
Conditions studied: Prostate Cancer
In brief
RATIONALE: Interleukin-2 may stimulate a person's white blood cells including natural killer cells to kill prostate cancer cells. Interferon gamma may interfere with the growth of the cancer cells. Combining interferon gamma with interleukin-2 may be a more effective treatment for prostate cancer. PURPOSE: Phase I/II trial to study the effectiveness of biological therapy using interleukin-2 and interferon gamma in treating patients with advanced prostate cancer.
Key facts
- Study ID
- NCT00002637
- Run by
- Memorial Sloan Kettering Cancer Center
- People needed
- 25
- Starts
- 1995-01-01
- Expected to finish
- 2001-02-01
- Last updated by the study team
- 2013-06-25
Who can join
Age: 18 and older. Sex: male. Healthy volunteers: not accepted.
Where it is running
- Memorial Sloan-Kettering Cancer Center — New York, New York, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.